Trial Profile

Phase II study of amikacin in cystic fibrosis patients with nontuberculous mycobacterial infections

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 25 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

21 Oct 2021 According to an Matinas BioPharma Media release, the company expects to initiate this study by the first quarter of 2023, following required longer-term preclinical toxicology studies to be conducted during 2022.
10 May 2021 According to an Matinas BioPharma Media release, the company expects to initiate this trial in 2022.
20 Dec 2020 According to a Matinas BioPharma media release, the Cystic Fibrosis Foundation (CFF) has indicated to the company a willingness to consider a request for monetary support for the continuation of clinical studies, including dose determination and Phase 2 efficacy studies in CF patients suffering from NTM lung disease.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com